Overview

A Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
0
Participant gender:
All
Summary
The investigators hypothesise that long term statin treatment will improve patients' symptoms through its anti-inflammatory effect. The beneficial effects on patient symptoms (cough, sputum volume, bacterial load, airway function, exercise tolerance, exacerbation frequency and health related quality of life) will be consequent on reduced neutrophilic airways inflammation.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Edinburgh
Collaborator:
NHS Lothian
Treatments:
Anti-Inflammatory Agents
Atorvastatin
Atorvastatin Calcium
Criteria
Inclusion Criteria:

- Patients aged 18-75 will be recruited. All will have an established radiological
diagnosis of bronchiectasis (CT of the chest). Patients will have clinically
significant bronchiectasis expectorating mucopurulent or purulent sputum when
clinically stable with at least 2 chest infections per year.

Exclusion Criteria:

- current smokers or ex-smokers of less than 1 year; >15 pack year history

- cystic fibrosis

- active allergic bronchopulmonary aspergillosis

- active tuberculosis

- poorly controlled asthma

- pregnancy or breast feeding

- known allergy to statins

- active malignancy

- chronic liver disease

- established cardiovascular or cerebrovascular disease

- statin use in the last year

- patients on long term oral macrolides due to the interaction with statin therapy
patients chronically colonised with Pseudomonas aeruginosa (defined as two or more
isolates of Pseudomonas aeruginosa whilst clinically stable in 6 months prior to the
study).